SCHEMBL7829295

SCHEMBL7829295

CC(=O)NCCCCCCCCCCCCC(C)C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.70
MAPK1 P28482 1/20 0.70
HIF1A Q16665 1/20 0.70
PAOX Q6QHF9 3/20 0.57
ADRA1A P35348 1/20 0.55
FOLH1 Q04609 1/20 0.47
EPHX1 P07099 4/20 0.44
ZDHHC7 Q9NXF8 1/20 0.42
SIRT6 Q8N6T7 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
TSHR P16473 1/20 0.41
KDM4C Q9H3R0 2/20 0.41
KDM4A O75164 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
ALDH1A1 P00352 2/20 0.40
ALDH1A2 O94788 1/20 0.40
ALDH2 P05091 1/20 0.40
ALDH1A3 P47895 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15981282 1.00 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL21227771 1.00 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL20859598 1.00 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL4762422 0.98 KDM4E (0.65) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL4762361 0.91 KDM4E (0.61) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL21106551 0.88 KDM4E (0.53) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL21106927 0.87 KDM4E (0.52) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL15238241 0.84 EPHX1 (0.60) KDM4EMAPK1HIF1AEPHX1KDM4C
SCHEMBL14739904 0.83 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL1900654 0.83 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7179339-A None JP disclosed
JP-6092844-A None JP disclosed
US-20250387442-A1 BACTERIA-TARGETING CAPSID PARTICLE, TREATMENT COMPOSITION, DISINFECTANT, FOOD, BACTERIA ELIMINATION METHOD, BACTERICIDAL METHOD, CORROSION PREVENTION METHOD, ANIMAL TREATMENT METHOD, GENE INTRODUCTION METHOD, BACTERIA FUNCTION ADDITION METHOD, METHOD FOR PRODUCING BACTERIA-TARGETING CAPSID PARTICLE, AND METHOD FOR PRODUCING NUCLEIC ACID FOR BACTERIA-TARGETING CAPSID PARTICLE JICHI MEDICAL UNIVERSITY (JP) 2025-12-25 US disclosed
US-20250295713-A1 COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES DERMBIONT, INC. 2025-09-25 US disclosed
EP-4549558-A1 BACTERIA-TARGETING CAPSID PARTICLE, TREATMENT COMPOSITION, DISINFECTANT, FOOD, METHOD FOR ELIMINATING BACTERIA, STERILIZATION METHOD, METHOD FOR PREVENTING DECAY, METHOD FOR TREATING ANIMAL, METHOD FOR INTRODUCING GENE, METHOD FOR ADDING BACTERIA FUNCTION, METHOD FOR PRODUCING BACTERIA-TARGETING CAPSID PARTICLE, AND METHOD FOR PRODUCING NUCLEIC ACID FOR BACTERIA-TARGETING CAPSID PARTICLE Jichi Medical University (JP) 2025-05-07 EP disclosed
US-12064459-B2 Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes DERMBIONT, INC. (US) 2024-08-20 US disclosed
WO-2024004923-A1 BACTERIA-TARGETING CAPSID PARTICLE, TREATMENT COMPOSITION, DISINFECTANT, FOOD, METHOD FOR ELIMINATING BACTERIA, STERILIZATION METHOD, METHOD FOR PREVENTING DECAY, METHOD FOR TREATING ANIMAL, METHOD FOR INTRODUCING GENE, METHOD FOR ADDING BACTERIA FUNCTION, METHOD FOR PRODUCING BACTERIA-TARGETING CAPSID PARTICLE, AND METHOD FOR PRODUCING NUCLEIC ACID FOR BACTERIA-TARGETING CAPSID PARTICLE 学校法人自治医科大学 2024-01-04 WO disclosed
US-20220160617-A1 COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES DERMBIONT, INC. 2022-05-26 US disclosed
CN-114302953-A Bacillus strain and method for promoting plant growth 奥本大学 2022-04-08 CN disclosed
JP-2001226328-A INTERMEDIATE OF CAPSIAMIDE AND IMPROVED METHOD FOR PRODUCING CAPSIAMIDE GRELAN PHARMACEUT CO LTD 2001-08-21 JP disclosed
JP-H07179339-A ANTI-INFLAMMATORY ANALGESIC AGENT OSAWA KEISUKE 1995-07-18 JP disclosed
JP-H0692844-A ANALGESIC AGENT OSAWA KEISUKE 1994-04-05 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387442-A1 BACTERIA-TARGETING CAPSID PARTICLE, TREATMENT COMPOSITION, DISINFECTANT, FOOD, BACTERIA ELIMINATION METHOD, BACTERICIDAL METHOD, CORROSION PREVENTION METHOD, ANIMAL TREATMENT METHOD, GENE INTRODUCTION METHOD, BACTERIA FUNCTION ADDITION METHOD, METHOD FOR PRODUCING BACTERIA-TARGETING CAPSID PARTICLE, AND METHOD FOR PRODUCING NUCLEIC ACID FOR BACTERIA-TARGETING CAPSID PARTICLE CLPP, CAPG, RNGTT KDM4E 4082/4885MAPK1 3137/4885HIF1A 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.